Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
RareCan logo — RareCan aims to accelerate research and ultimately improve t...

RareCan

RareCan aims to accelerate research and ultimately improve treatments and outcomes for people with rare cancers.

Founded 2019 United Kingdom United Kingdom 8 employees Equity Crowdfunding Total: $576.88K Biotechnology, Health Care

General Information

Company Name RareCan
Founded Year 2019
Location United Kingdom United Kingdom +1
Employees 8
Industries Biotechnology, Health Care
Funding Stage Equity Crowdfunding
Social

Get notified when RareCan moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About RareCan

RareCan is a United Kingdom-based biotechnology and healthcare company, founded in 2019, with a mission to accelerate research and improve treatments for individuals with rare cancers. The company has recently secured a £374.88K Equity Crowdfunding investment on 15 June 2022 through Crowdcube. RareCan addresses the pressing need for rapid access to consenting patients, secure data, and bio-samples for researchers working on rare cancers. The company's innovative platform connects consenting patients with leading researchers, creating a large and growing patient community with a BioResource. This provides researchers with access to tissue and blood samples, as well as genetic data, thereby reducing the time taken to provide samples for research purposes from months to weeks. One of RareCan's key strengths lies in its ability to build precise cohorts of trial participants, enabling the delivery of histology-independent trials targeting genetic mutations common across different rare cancer types. This positions RareCan at the forefront of advancing clinical research into rare cancers. Supported by a network of NHS Trusts and patient organizations, including GIST Cancer UK, RareCan is uniquely positioned as the first and only company in the market to integrate 'consent to contact' patient recruitment, abundant data for accurate screening, and access to bio-samples and genetics. This places RareCan at the forefront of driving progress in clinical research, making it a compelling investment opportunity for venture capitalists seeking to support breakthrough innovations in the biotechnology and healthcare industries.

Taxonomy: rare cancers, clinical trials, patient recruitment, research acceleration, bio-samples, genetic data, NHS Trusts, patient organizations, cancer research, data access, treatment outcomes, precision cohort, histology-independent trials, life sciences companies, global research network

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Equity Crowdfunding •••••• 1
Investor
15 Jun 2022
Seed Round •••••• 1
Investor
23 Mar 2021
Grant •••••• 1 •••• •••• 01 Jan 2021

RareCan Alternatives & Competitors

RareCan vs
Power
Power United States

We are a Modern Clinical Trial Marketplace. We help patients access research and help trials recruit...

Series A
259 employees
Health Care, Medical Devices
RareCan vs
Clinerion Ltd
Clinerion Ltd Switzerland

Imagine faster patient access to medicines and improved health outcomes with Clinerion real world da...

12 employees
Digital Health, Health Care
RareCan vs
Concr
Concr United Kingdom

Predict cancer treatment benefit for every patient using multimodal data

Grant
9 employees
Biopharma, Biotechnology

FAQ About RareCan

RareCan aims to accelerate research and ultimately improve treatments and outcomes for people with rare cancers.
RareCan was founded in 2019.
RareCan is headquartered in United Kingdom.
RareCan operates in the following industries: Biotechnology, Health Care.
RareCan has approximately 8 employees.
RareCan has completed 3 funding rounds, raising a total of $576.88K. The latest funding stage is Equity Crowdfunding.
Top alternatives and competitors to RareCan include Power, Clinerion Ltd, Concr, ClinOne, Genomenon, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RareCan and Power are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors RareCan and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy